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Background: Over the last decade the use of psychotropic medications to treat common mental health problems
has increased in Australia. This paper explores: 1) public attitudes towards the acceptability of using prescription
drugs to treat depression and attention deficit hyperactivity disorder (ADHD), and 2) beliefs about over-diagnosis of
depression and ADHD.
Method: 1293 members of the general public were surveyed about their attitudes towards drug treatment for
depression and ADHD through the Queensland Social Survey (QSS), an omnibus state-wide survey of households in
the state of Queensland. The survey was administered through a CATI (computer-assisted telephone interviewing)
system. Logistic regression analyses were used to predict belief that drug treatment is acceptable, and that depression
and ADHD are over-diagnosed.
Results: Most participants (60.9%) said that it was acceptable to use prescription drugs to treat depression. In contrast,
attitudes towards the use of prescription drugs to treat ADHD were much less positive with around the same proportion
saying it was acceptable (42.1%) as unacceptable (38.2%). More than half of the sample agreed that too many people
are diagnosed with depression when they don’t really have it (57.7%), and 78.3% of participants agreed that too many
children are diagnosed with ADHD when they don’t really have it. Participants who said depression or ADHD were
over-diagnosed were less likely to say that it is acceptable to treat these conditions with prescription drugs.
Conclusions: Despite increases in prescribing rates there is still considerable scope for increasing the public’s
acceptance of treating common mental illnesses with psychotropic drugs. Furthermore, the public’s views on
over-diagnosis of depression and ADHD appear to reflect ongoing controversy about the proper identification of
these conditions, and these views negatively impact attitudes towards drug treatment. This may be a barrier to effective
treatment of these conditions given that drug treatment is often recommended as a first line response.
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Over the last decade the use of psychotropic medications
to treat common mental health problems has increased in
Australia. In particular, increases in prescribing rates for
anti-depressants and stimulants (typically used in the treat-
ment of Attention Deficit Hyperactivity Disorder) were
among the highest for all psychotropic drugs. A recent* Correspondence: b.partridge@uq.edu.au
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scribing rates rose 95% for antidepressants and 72% for
ADHD drugs between 2000 and 2011 [1].
While it is clear that doctors are prescribing more psy-
chotropic drugs, we know less about people’s attitudes
towards drug treatment. Attitudes towards psychotropic
drugs are an important part of the public’s “mental
health literacy” [2,3] that may influence willingness to
start using these drugs and continue to use them. The
overall upward trend in the prescribing of psychotropical Ltd. This is an Open Access article distributed under the terms of the Creative
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awareness of mental illness (which may indicate in-
creased treatment seeking on the part of patients) and a
growing acceptance of psychotropic medications as an
acceptable method of treatment for mental disorders [1].
Understanding public attitudes towards drug treatment
is therefore an important part of understanding prescrib-
ing trends.
Public attitudes towards the use of anti-depressants
have gradually become more favourable in Australia
[4,5]. In 2011 we surveyed 1265 members of the
Queensland public (as part of the Queensland Social
Survey; QSS) finding that most people (55%) believed it
was acceptable to use prescription drugs to treat depres-
sion; however, around 15% disagreed outright and almost
30% were unsure or neutral, indicating that there is con-
siderable room for full acceptance of anti-depressants [6].
The two-thirds of participants had either been treated for
depression with prescription drugs or knew someone
who had, were more likely to view drug treatment as
acceptable.
There is good evidence that public attitudes towards
drug treatment are not uniform across mental disorders
[7]. Our 2011 survey found that attitudes towards the
use of stimulants to treat ADHD were sharply divided.
The acceptability of drug treatment for ADHD was
much lower than for depression (35%) and an almost
equal number disagreed outright with such treatment
[6]. While there is evidence that parents of children with
ADHD are more likely to be accepting of stimulant
treatment [8], other studies with Australian parents have
found that those whose child had been diagnosed with
ADHD are more likely to think that too many children
are medicated for ADHD and two-thirds also thought
that ADHD was over-diagnosed [9].
Are attitudes towards over-diagnosis related to views
about drug treatment?
Widening diagnostic criteria, off-label use drugs, and
effective pharmaceutical industry marketing have also
been suggested as factors contributing to the rise in
psychotropic prescribing in Australia [1]. Some view
this as evidence that increased prescribing is in fact the
result of over-diagnosis and/or over-treatment of mental
disorders [10]. Drug treatment is often the first line re-
sponse to a diagnosis of depression or ADHD. However,
the increase in stimulant prescribing in Australia has
occurred amid ongoing worldwide controversy about the
proper identification and diagnosis of ADHD in the first
place [11,12].
Some studies have uncovered concerns that behaviours
such as inattentiveness and excitability may be misattribu-
ted as symptoms of ADHD in some children (particularly
boys), leading to suggestions that ADHD is over-diagnosedand stimulant drugs are being used without good cause
[13]. A similar controversy exists about the over-use of an-
tidepressants for depression [14-16]. While a number of
health initiatives appear to have been successful at increas-
ing the likelihood that sufferers of depression will seek and
receive help [17], critics have suggested that increased pre-
scribing of anti-depressants is often inappropriate and of
questionable value [14].
The potential risks of unnecessary use of psychotropic
medications include exposure to the side effects of drug
treatment; a waste of financial resources on the part of the
patient and the health care system; and potentially negative
social effects of drug treatment, including stigma.
If the public believes mental illnesses are over-
diagnosed and drug treatments are over-used as a result,
then this may impact their attitudes towards the accept-
ability of treating these disorders with psychotropic medi-
cations. A belief that mental illnesses are over diagnosed
and that drugs are overused may even deter some people
from seeking help (which may not necessarily involve
medication) even when they need it, thereby missing out
on appropriate treatment. This may present an obstacle to
effective treatment of mental disorders. There is a clear
need to better understand public beliefs about over-
diagnosis of mental disorders and their relationship to atti-
tudes towards the acceptability of drug treatment of mental
disorders.
The current study
This study extends our 2011 study of public attitudes to-
wards the acceptability of psychotropic drug treatment
for ADHD and depression [6] by including an explor-
ation of public attitudes towards over-diagnosis of these
conditions. We again surveyed attitudes towards the ac-
ceptability of drug treatment for depression and ADHD
given that: 1) anti-depressants and stimulants have in-
creased more than almost all other psychotropic drugs,
2) there is ongoing discussion about over-diagnosis of
both conditions, and 3) our previous study indicated
relatively high levels of familiarity with both disorders
among the general public.
Here we use data from the 2013 Queensland Social
Survey. Our aims were to explore: 1) attitudes towards
the acceptability of pharmacological treatment for de-
pression and ADHD; 2) the extent to which attitudes
were similar for the two disorders, 3) participants’ famil-
iarity with people who have been treated for these two
conditions using prescription drugs (e.g. have you or
anyone you know personally been treated for depres-
sion/ADHD with prescription drugs?), and 4) the extent
to which ‘familiarity’ is related to attitudes towards the
acceptability of pharmacological treatment for depres-
sion and ADHD. These aims carry over from the 2011
study, allowing us to compare the 2011 and 2013 results.
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The sample comprised 1293 participants: 671 males and
622 females (aged 18+ years; mean = 56.3). Older people
were over-sampled when compared with the Australian
Bureau of Statistics (ABS) census data for the Queensland
population (those over 55 years of age were comprised
55.6% of the sample). Those aged under 35 years com-
prised 7.9% of the sample and those aged 35–54 years
comprised 35.9%.
The survey instrument: the Queensland social survey
Data collection was between June and August 2013
through the Queensland Social Survey (QSS), which is
an omnibus style state-wide survey of households in the
state of Queensland, Australia. The QSS is adminis-
tered through a CATI (computer-assisted telephone
interviewing) system at Central Queensland University
(CQU). The CATI is implemented by a human inter-
viewer who follows a computer guided series of survey
questions from multiple research bodies and other orga-
nizations on a wide range of topics. Ethics approval for
the study was granted by the CQU Human Research
Ethics Committee. Participants were asked the extent to
which they agreed with the following statements explor-
ing attitudes towards the acceptability of drug treatment
for depression and ADHD and their belief that these dis-
orders are “over-diagnosed”:
Q1. It is acceptable for prescription drugs, such as
Prozac, to be used in the treatment of depression.
Q2. Far too many people in Australia are diagnosed
with depression when they don’t really have it.
(Over-diagnosed)
Q3. It is acceptable for prescription drugs, such as
Ritalin, to be used in the treatment of ADHD
(Attention Deficit Hyperactivity Disorder).
Q4. Far too many children in Australia are diagnosed with
ADHD when they don’t really have it. (Over-diagnosed)
Participants were asked to answer using the following
response categories: (1) strongly agree; (2) agree; (3) slightly
agree; (4) slightly disagree; (5) disagree; (6) strongly dis-
agree; (7) don’t know. In Australia, Prozac and Ritalin are
widely prescribed for the treatment of depression and
ADHD, respectively, and are commonly mentioned in the
media discourse about these conditions; we mentioned
them by name to aid participant understanding.Next, participants were asked about their familiarity
with persons who have been treated for depression or
ADHD with prescription drugs:
Q5. Have you, or someone you know personally, ever
been treated for depression with prescription drugs?
Q6. Have you, or someone you know personally, ever
been treated for ADHD with prescription drugs?
Participants were asked to answer according to the fol-
lowing format: (1) yes – I have; (2) yes – someone I
know personally has; (3) yes – both myself and someone
I know personally; (4) no; (5) don’t know.
Procedure
The target population for the telephone interview con-
sisted of persons 18 years of age or older who, at the
time of the survey, were living in Queensland and could
be contacted by direct-dialled, land-based telephone ser-
vice. The response rate was 41.2%. The sample was drawn
from a telephone database by using a computer program
to select a random sample of phone numbers. Within the
household, one eligible person was selected as the respond-
ent for the interview whilst ensuring an equal yet random
selection of male and female participants. Participants
granted verbal consent to participate.
Analysis
Descriptive analyses gave overall rates of: agreement
with the acceptability of using prescription drugs to treat
depression and ADHD; agreement that too many people/
children are diagnosed with depression and ADHD; and
overall rates of familiarity with drug treatment for depres-
sion and ADHD.
Two logistic regression analyses were conducted (one
for depression and one for ADHD) to predict agreement
with the acceptability of using prescription drugs to treat
the disorder. The dependent variable was ‘It is acceptable
to use prescription drugs’ coded as disagree = 0; agree = 1.
The predictor variables were: gender (male = 0 (ref );
female = 1); years of education (1-10 yrs = 0 (ref ); 11-
12 yrs = 1; 13-14 yrs = 2; 15 yrs + = 3); age (18–34 = 0; 35–
44 = 1; 45–54 = 2; 55+ = 3); over-diagnosis (disagree = 0;
agree = 1); and familiarity with the relevant disorder
(not familiar = 0 (ref ); yes – other = 1; yes – me = 2).
For ADHD, the familiarity variable was coded as (not
familiar = 0 (ref); yes – me or other = 1), due to the small
number of participants who had actually been diagnosed
with ADHD.
We also conducted two logistic regression analyses to
predict agreement that 1) depression is over-diagnosed,
and 2) ADHD is over-diagnosed. Predictor variables in
these regression models were the demographic variables
age, gender, education, and familiarity as described above.
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Most participants (60.9%) said that it was acceptable to
use prescription drugs to treat depression; only 17.5%
expressed outright disagreement. In contrast, attitudes
towards the use of prescription drugs to treat ADHD
were much less positive with around the same propor-
tion saying it was acceptable (42.1%) as unacceptable
(38.2%). For both depression and ADHD, almost one-
in-five participants answered “Don’t Know” (21.6%
for depression and 19.6% for ADHD).
Depression
1) Over-diagnosis of depression. More than half of the
sample agreed that too many people are diagnosed
with depression when they don’t really have it
(57.7%), and 22.9% disagreed that this was the case
(19.4% did not know). Of the participants who
thought depression was over-diagnosed, 58.6% said
drug treatment is acceptable. Those who did not
think depression is over-diagnosed were more likely
to agree that drug treatment is acceptable (77.3%)
(see Table 1).Table 1 Agreement with the statement ‘it is acceptable
for prescription drugs to be used in the treatment of
depression’ according to ‘familiarity’ and ‘attitudes
towards over-diagnosis’
Acceptable for prescription drugs to
treat depression
N (%) Agree (%) Disagree (%) Don’t
know (%)
Total sample 1269 60.9 17.5 21.6
Depression is over-
diagnosed
Agree 732 58.6 24.0 17.3
Disagree 291 77.3 9.6 13.1
Don’t know 109 48.4 7.3 44.3
Familiarity with
depression
Not Familiara 422 51.4 17.3 31.3
Yes – otherb 593 63.2 18.7 18.0
Yes – mec 264 70.8 15.2 14.0
Age category
18 – 34 101 74.3 13.9 11.9
35 – 44 199 70.4 10.1 19.6
45 – 54 262 67.2 14.5 18.3
55+ 708 54.2 20.9 24.9
aNot familiar = I don’t know anyone who has been treated for depression with
prescription drugs.
bYes – other = I personally know someone who has been treated for
depression with prescription drugs.
cYes – me = I have been treated for depression with prescription drugs.2) Familiarity. Two-thirds of the sample was familiar
with someone who had been treated for depression
with prescription drugs (67%) – either someone they
personally knew (46.4%) or themselves (20.6%). The
remainder (33%) did not know anyone who had been
treated for depression with prescription drugs (“Not
Familiar”). Fewer participants in the “Not Familiar”
group believed that drug treatment was acceptable
(51.4%) compared to those who did know someone
who had been treated (63.2%), and those who had
been treated themselves (70.8%). Almost a third of
participants in the “Not Familiar” group answered
“Don’t know” (30.3%) compared to participants who
either knew someone who had been treated with
drugs for depression (18%) or who had been treated
themselves (14%).
3) Predicting positive attitudes towards the acceptability
of drug treatment for depression. A logistic
regression analysis was used to assess the impact of
a number of factors on agreement with the
proposition that it is acceptable to use prescription
drugs to treat depression. The full model was able to
distinguish between respondents who expressed
outright agreement with the acceptability of using
drugs to treat depression and those who did not
[x2 (10, N = 844) = 61.584, p < .001]. Table 2 shows that
participants who said that depression is over-diagnosed
were 3.2 times less likely to think that drug treatment
for depression is acceptable. Younger participants
(18–34 years) were 2 times more likely than older
participants (55 years +) to think that drug treatment
for depression is Acceptable.
4) Predicting the belief that depression is over-diagnosed.
People who were not familiar with anyone who had
undergone drug treatment for depression were much
more likely to think that depression is over-diagnosed
[x2 (9, N = 1014) = 54.525, p < .001]. Participants with
1–10 years of education were more likely to think
depression is over-diagnosed compared to those with
13–14 and 15+ years of education (see Table 3).
ADHD
1) Over-diagnosis of ADHD. The overwhelming
majority of participants agreed that too many
children are diagnosed with ADHD when they don’t
really have it (78.3%), and only 8.4% of participants
disagreed. Among those who said ADHD is over-
diagnosed, 41.5% said drug treatment for ADHD is
acceptable, whereas 59.4% of participants who did not
think ADHD is over-diagnosed said drug treatment is
acceptable (see Table 4).
2) Familiarity. Most participants (61.1%) did not know
anyone who had been treated for ADHD with
Table 3 Predictors of the belief that depression is
over-diagnosed
Predictor Odds 95% CI
Familiarity
Not familiara 1 -
Yes - otherb .74 .52 – 1.04
Yes - mec .43*** .28 – .64
Gender
Female .99 .74 – 1.31
Age (years)
18 – 34 1 -
35 – 44 .85 .48 – 1.51
45 – 54 .87 .50 – 1.50
55+ 1.21 .72 – .2.03
Education
1 – 10 years 1 -
11 – 12 years .68 .43 – 1.08
13 – 14 years .57* .35 – .94
15+ years .41*** .27– .61
*p<. 05; ***p < .001.
aNot familiar = I don’t know anyone who has been treated for depression with
prescription drugs.
bYes – other = I personally know someone who has been treated for
depression with prescription drugs.
cYes – me = I have been treated for depression with prescription drugs.
Table 2 Predictors of agreement with the statement: “it is
acceptable for prescription drugs to be used in the
treatment of depression”
Predictor Odds 95% CI
Over-diagnosed
Yes .31*** .19 – .49
Familiarity
Not familiara 1 -
Yes - otherb 1.16 .79 – 1.71
Yes - mec 1.53 .93 – 2.52
Gender
Female .93 .66 – 1.31
Age (years)
18 – 34 1 -
35 – 44 1.22 .54 – 2.76
45 – 54 .71 .34 – 1.48
55+ .49* .25 – .97
Education
1 – 10 years 1 -
11 – 12 years .95 .58 – 1.55
13 – 14 years 1.16 .66 – 2.01
15+ years 1.21 .79 – 1.87
*p<. 05; ***p < .001
aNot familiar = I don’t know anyone who has been treated for depression with
prescription drugs.
bYes – other = I personally know someone who has been treated for
depression with prescription drugs.
cYes – me = I have been treated for depression with prescription drugs.
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someone who had been treated, and only 3.7% had
been treated themselves. The ratio of agree/disagree
responses was slightly higher for the two “Familiar”
groups compared to those who did not know
anyone treated for ADHD with drugs. Those in the
“Not Familiar” group had the lowest overall rate of
agreement with the acceptability of drug treatment
for ADHD (36.5%), however a much higher
proportion of people in the “Not Familiar” group
also answered “Don’t know” (27.1%), compared to
the two “Familiar” groups.
3) Predicting positive attitudes towards the acceptability
of drug treatment for ADHD. For ADHD, the full
regression model was also statistically significant and
able to distinguish between respondents who
expressed outright agreement, and those who
disagreed, with the use of drugs to treat ADHD,
[x2 (8, N = 930) = 46.489, p < .001]. Table 5 shows that
familiarity, over-diagnosis, education and age
were significant predictors, while gender was not.
Compared to participants in the “Not Familiar” group,
those who knew someone who had received drugtreatment for ADHD (or had themselves been treated)
were 1.3 times more likely to agree that drug treatment
is acceptable. As with depression, the belief that
ADHD is over-diagnosed was associated with less
favourable attitudes towards the acceptability of drug
treatment. In addition, participants with 15+ years of
education were 1.75 times more likely to agree that
drug treatment for ADHD is acceptable compared
to those with 1–10 years of education. As with
depression, younger participants (18–34 years) were
more likely than older participants (55+) to say that
drug treatment for ADHD is acceptable. The
regression model predicting the belief that ADHD is
over-diagnosed was not significant, indicating that
demographic variables (including familiarity) were not
directly related to attitudes towards over-diagnosis,
[x2 (8, N = 1089) = 6.529, p = .588] (see Table 6).
Discussion
Prescriptions for anti-depressants and stimulants in
Australia have increased at a higher rate than almost all
other psychotropic medications over the last decade
[1,18,19]. However, there are ongoing concerns about the
extent to which this increased prescribing is accepted by
the public, has led to better health outcomes, or is symp-
tomatic of over-diagnosis of mental disorders [12].
Table 4 Agreement with the statement ‘it is acceptable
for prescription drugs to be used in the treatment of
ADHD’ according to ‘familiarity’ and ‘attitudes towards
over-diagnosis’
Acceptable for prescription drugs
to treat ADHD
N (%) Agree (%) Disagree (%) Don’t
know (%)
Total sample 1276 42.1 38.2 19.7
ADHD is over-
diagnosed
Agree 993 41.5 44.0 14.5
Disagree 106 59.4 31.1 9.4
Don’t know 169 34.3 9.5 56.2
Familiarity with ADHD
Not familiara 779 36.5 36.5 27.1
Yes – otherb 450 50.4 40.7 8.9
Yes – mec 47 55.3 42.6 2.1
Age category
18 – 34 101 56.4 33.7 9.9
35 – 44 198 41.9 37.9 20.2
45 – 54 260 52.3 35.0 12.7
55+ 708 36.2 40.1 23.7
aNot familiar = I don’t know anyone who has been treated for ADHD with
prescription drugs.
bYes – other = I personally know someone who has been treated for ADHD
with prescription drugs.
cYes – me = I have been treated for ADHD with prescription drugs.
Table 5 Predictors of agreement with the statement: “it is
acceptable for prescription drugs to be used in the
treatment of ADHD”
Predictor Odds 95% CI
Over-diagnosed
Yes .53** .34 – .83
Familiarity
Not familiara 1 -
Yes - otherb d1.33* 1.02 – 1.74
Yes - mec
Gender
Female 1.03 .79 – 1.35
Age (years)
18 – 34 1 -
35 – 44 .59* .34 – 1.04
45 – 54 .82 .49 – 1.39
55+ .54* .33 – .88
Education
1 – 10 years 1 -
11 – 12 years 1.1 .73 – 1.64
13 – 14 years .83 .53 – 1.31
15+ years 1.75** 1.23 – 2.48
*p<. 05; **p < .01.
aNot familiar = I don’t know anyone who has been treated for ADHD with
prescription drugs.
bYes – other = I personally know someone who has been treated for ADHD
with prescription drugs.
cYes – me = I have been treated for ADHD with prescription drugs.
dIncludes participants who have been treated for ADHD with prescription
drugs or who know someone who has.
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acceptable to most members of the public (approx.
60%), although almost 40% disagreed or were unsure.
This result echoes our 2011 findings (see Table 7) [6]. In
Australia and the US, public views about the use of anti-
depressants have become more positive since the 1990s
[4,7]. In terms of overall support, some surveys suggest a
higher level of endorsement for anti-depressants in the
treatment of depression among members of the US pub-
lic compared to the participants in our survey [7]. Drug
treatment for depression was regarded as much more
acceptable than drug treatment for ADHD. Overall,
members of the public were ambivalent about the ac-
ceptability of using prescription stimulants to treat
ADHD, and only 42% agreed that drug treatment is
acceptable for ADHD. This is in line with our 2011 find-
ings and with US surveys showing that a minority of
members of the public would choose stimulant medica-
tion for a child, and most would prefer behavioural
interventions [20,21].
Our exploration of attitudes towards over-diagnosis
yielded results that health care professionals may find
concerning – that is, most participants believed that
depression and ADHD are over-diagnosed in the firstplace. In particular, around 78% of participants said that
too many children are diagnosed with ADHD when they
don’t actually have the disorder. And despite most par-
ticipants saying that drug treatment for depression is ac-
ceptable, nearly 58% said that too many people are
diagnosed with depression when they don’t really have
it. Importantly, people who thought that depression or
ADHD were over-diagnosed were less likely to think that
it is acceptable to use prescription drugs to treat these
disorders. This raises the prospect that scepticism about
drug treatment may be partly based on scepticism about
the appropriateness of the diagnosis. Some members of
the public who believe that depression and ADHD are
too readily diagnosed may be reluctant to seek help from
a health care provider even when they (or their children)
need it. This may be for a number of reasons including
concerns about unnecessary drug treatment and fear of
being stigmatised by having a mental health problem. In
such cases, perceptions about over-diagnosis and over-
treatment could in fact result in some people in genuine
need for help going untreated. One other potential
Table 7 Reponses to the statements “it is acceptable to
use prescription drugs to treat Depression/ADHD”: 2013
and 2011 results
Depression (%) ADHD (%)
2013 2011a 2013 2011a
Agree 60.9 61.4 42.1 39.2
Disagree 17.5 16.7 38.2 39.3
Don’t Know 21.6 21.9 19.6 21.5
a2011 data included a “Neutral” option accounting for 9.6% of the sample for
depression, and 9.2% for ADHD. The percentages reported here have been
re-calculated by excluding “Neutral” respondents from the denominator for
direct comparison with 2013 data.
Table 6 Predictors of the belief that ADHD is
over-diagnosed
Predictor Odds 95% CI
Familiarity
Not familiara 1 -
Yes - otherb d.76 .50 – 1.14
Yes - mec
Gender
Female .90 .59 – 1.36
Age (years)
18 – 34 1 -
35 – 44 .93 .42 – 2.03
45 – 54 1.28 .59 – 2.78
55+ 1.47 .72 – 3.01
Education
1 – 10 years 1 -
11 – 12 years 1.02 .54 – 1.91
13 – 14 years 1.25 .60 – 2.59
15+ years .93 .54 – 1.61
aNot familiar = I don’t know anyone who has been treated for ADHD with
prescription drugs.
bYes – other = I personally know someone who has been treated for ADHD
with prescription drugs.
cYes – me = I have been treated for ADHD with prescription drugs.
dIncludes participants who have been treated for ADHD with prescription
drugs or who know someone who has.
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ceive a diagnosis of depression or ADHD may be more
reluctant to initiate or continue drug treatments if they
believe these conditions are typically over-diagnosed and
over-medicated. This may be a barrier to effective treat-
ment of these conditions given that drug treatment is
often recommended as a first line response. It may be
worthwhile for future research to explore how percep-
tions about diagnosis and treatment influence actual
treatment seeking behaviour. For ADHD especially, it
would be useful for future studies to explore in greater
detail how attitudes towards stimulant prescribing are
related to attitudes towards the diagnosis of ADHD, and
to the use of stimulant medication. Parents of a child
with ADHD may have concerns about the side-effects of
stimulant treatment however these concerns may be
amplified if they harbour doubts about the proper diag-
nosis of ADHD.
Members of the Australian public in this study showed
high levels of familiarity with drug treatment both
conditions – around 67% of participants had either been
treated for depression with prescription drugs or person-
ally knew someone who had (65.4% in 2011). Approxi-
mately 35% knew someone who had been treated for
ADHD with stimulants (28.7% in 2011). Our explorationof other factors predicting positive attitudes towards the
acceptability of drug treatment yielded slightly different
results to 2011. Knowing someone who had been treated
for depression with prescription drugs (or having been
treated oneself ) was not a significant predictor of positive
attitudes towards the acceptability of drug treatment for
depression – unlike our 2011 survey. While our 2013 re-
sults showed a clear trend towards familiarity being a
predictor, it did not reach statistical significance. Other
studies with members of the Australian public have sug-
gested that familiarity may be associated with more
favourable attitudes towards drug treatment. For example
there is evidence that Australians who know someone
with depression are less likely to think anti-depressants
are harmful [22]. Studies in other countries have found
similar results [23]. For ADHD, familiarity was a signifi-
cant predictor of more positive attitudes towards the ac-
ceptability of drug treatment in the current study – the
2011 analysis did not reach significance. This is again an
area that well designed qualitative studies could help to
elucidate the nature of the relationship between these
variables. While familiarity may lend a greater insight
into the potential benefits of drug treatment, those who
personally know a child treated for ADHD with prescrip-
tion drugs are also likely to be acutely aware of any nega-
tive side-effects.
Although age was not a significant predictor of atti-
tudes towards over-diagnosis, older people were much
less likely to say that drug treatment for depression or
ADHD is acceptable. This finding warrants further ex-
ploration given that older people were over-represented
in this sample and participants over 55 years of age were
more likely to answer “don’t know”. Compared to all
other age categories, those aged 18–34 were far less
likely to answer “don’t know”.
Attitudinal surveys can provide a useful snapshot of
the public viewpoints. The usefulness and robustness of
their findings can be increased if they are repeated. Al-
though there has been an increase in the prescription of
drugs to treat depression and ADHD, the findings from
the 2013 QSS and 2011 QSS indicate that there is still
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public that drug treatment is acceptable or warranted.
Addressing the belief that these disorders are over-
diagnosed appears to be one part of this. This survey
could be conducted again in the future to essentially
track attitudes towards these issues over time and fur-
ther elucidate the factors that influence attitudes. The
major limitation of using the sample described in this
study is that younger people are under-represented. While
this is not unusual for CATI surveys with the general
community, it does mean that it would be prudent not to
overgeneralise these findings. Under representation of
younger people often occurs in CATI surveys that source
landline phones only, and dual frame (landline and mo-
bile) surveys may improve the representativeness of future
surveys. Nevertheless the survey tool could easily be used
with other representative cohorts for direct comparisons
or extended to explore other domains relevant to public
attitudes towards the acceptability of drug treatment (as
we did in the 2013 survey by extending the analyses to ex-
plore “over-diagnosis”). This would potentially improve
the explanatory power of the survey tool by taking into ac-
count a larger number of variables that inform attitudes.
The survey could also be adapted to investigate attitudes
towards the acceptability of drug treatment for other
common mental illnesses such as anxiety and various
substance use disorders. This would provide a broader
understanding of the spectrum of public attitudes to-
wards pharmacological drug treatment. Elsewhere, we
have used a variation of this survey to explore attitudes
towards the acceptability of healthy people using pre-
scription drugs for “cognitive enhancement” [24].
Conclusions
This paper demonstrates the importance of under-
standing public attitudes towards treatments for dis-
orders such as depression and ADHD. Most members of
the public thought depression and ADHD were over-
diagnosed, although they were more accepting of drug
treatment for depression compared to ADHD. Increases
in the prescription of psychotropic medication may not
result in better treatment if there are widespread public
attitudes that do not support the use of drug treatment
for these conditions. Further research about public atti-
tudes may provide helpful insights into ways in which
treatment for depression and ADHD may be better man-
aged. In particular, it would be worthwhile investigating
what members of the public and/or health care profes-
sionals think should be done to avoid over-diagnosis (for
example, requiring parent and teacher data to inform an
ADHD diagnosis, or restricting the diagnosis to major
types of impairment) and to avoid overtreatment (for
example, trying cognitive behavioural therapy for depres-
sion before prescribing antidepressants).Competing interests
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